Market Access News | pharmaphorum

News

After FDA nod, Eisai and Biogen file lecanemab in EU

Eisai and Biogen have moved swiftly ahead with regulatory filings for their new Alzheimer's therapy lecanemab in the EU, after getting a green light for the anti-amyloid beta antibody in th

News

Free access to Zolgensma curbed, says Novartis

Novartis' programme providing free access to its spinal muscular atrophy (SMA) gene therapy Zolgensma is being scaled back to a dozen countries worldwide, according to the company.

News

Alzheimer's drug Leqembi to launch at discount to Aduhelm

Eisai and Biogen's Alzheimer's therapy Leqembi will be priced at $26,500 per year – a little less than misfired predecessor Aduhelm – after getting conditional authorisation for the drug fr

News

FDA starts review of Sanofi, AZ antibody for RSV prevention

The clock has started ticking on the FDA's review of Sanofi and AstraZeneca's one-shot antibody to protect newborns and infants from respiratory syncytial virus (RSV), with a decision due i

News

FDA clears way for retail pharmacy sale of abortion pills

Retail pharmacies in the US will be able to dispense mifepristone-based therapies to end pregnancies after the FDA introduced changes to its regulatory framework for the products.<

News

Tributes as former NICE, MHRA chair Sir Mike Rawlins dies

The UK healthcare sector is mourning one of the most eminent of its figures in the last few decades – Professor Sir Mike Rawlins – who has passed away at the age of 81.

After FDA nod, Eisai and Biogen file lecanemab in EU

Free access to Zolgensma curbed, says Novartis

Alzheimer's drug Leqembi to launch at discount to Aduhelm

FDA starts review of Sanofi, AZ antibody for RSV prevention

FDA clears way for retail pharmacy sale of abortion pills

Tributes as former NICE, MHRA chair Sir Mike Rawlins dies

Simple blood test could aid in global TB fight

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks